NAGE Q2 2023 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+21.5% YoY

Gross Profit

$12M60.8% margin

Operating Income

-$2M-11.4% margin

Net Income

-$2M-10.8% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

-9.9%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$53M

Total Liabilities

$26M

Stockholders' Equity

$27M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$17M	+21.5%
Gross Profit	$12M	$10M	+23.0%
Operating Income	-$2M	-$6M	+63.7%
Net Income	-$2M	-$6M	+65.7%